APA (7th ed.) Citation

Xiang, G., Huang, Y., Zhang, N., Du, X., Wu, Y., Gan, L., . . . Liu, Y. First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. SAGE Publishing.

Chicago Style (17th ed.) Citation

Xiang, Guiyuan, Yueyue Huang, Ni Zhang, Xinyu Du, Yuanlin Wu, Lanlan Gan, Yanping Li, Tingting Jiang, and Yao Liu. First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. SAGE Publishing.

MLA (9th ed.) Citation

Xiang, Guiyuan, et al. First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. SAGE Publishing.